These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 3222164)
41. A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women. Hemsell DL; Martens MG; Faro S; Gall S; McGregor JA Clin Infect Dis; 1997 Feb; 24 Suppl 2():S222-30. PubMed ID: 9126697 [TBL] [Abstract][Full Text] [Related]
42. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus. Embil JM; Soto NE; Melnick DA Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293 [TBL] [Abstract][Full Text] [Related]
43. The antimicrobial activity of imipenem/cilastatin and its treatment in critical ill patients with polymicrobial and mixed infection. Leu HS; Wu JL Changgeng Yi Xue Za Zhi; 1993 Sep; 16(3):154-63. PubMed ID: 8221288 [TBL] [Abstract][Full Text] [Related]
44. Clinical comparison of cefotaxime versus the combination of gentamicin plus clindamycin in the treatment of polymicrobial soft-tissue surgical sepsis. Strom PR; Geheber CE; Morris ES; Stone HH Clin Ther; 1982; 5 Suppl A():26-31. PubMed ID: 6293715 [TBL] [Abstract][Full Text] [Related]
45. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. Barie PS; Vogel SB; Dellinger EP; Rotstein OD; Solomkin JS; Yang JY; Baumgartner TF Arch Surg; 1997 Dec; 132(12):1294-302. PubMed ID: 9403533 [TBL] [Abstract][Full Text] [Related]
46. Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients. Laszlo D; Bacci S; Bosi A; Fanci R; Guidi S; Saccardi R; Vannucchi AM; Rossi Ferrini P J Chemother; 1997 Apr; 9(2):95-101. PubMed ID: 9176746 [TBL] [Abstract][Full Text] [Related]
47. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Jia B; Lu P; Huang W; Li C; Huang A; Zhou X; Zhang W; Wu G; Zhang G Chemotherapy; 2010; 56(4):285-90. PubMed ID: 20714145 [TBL] [Abstract][Full Text] [Related]
48. Imipenem-cilastatin vs. tobramycin and metronidazole for appendicitis-related infections. Uhari M; Seppänen J; Heikkinen E Pediatr Infect Dis J; 1992 Jun; 11(6):445-50. PubMed ID: 1608680 [TBL] [Abstract][Full Text] [Related]
49. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389 [TBL] [Abstract][Full Text] [Related]
50. Ceftriaxone versus imipenem/cilastatin as empirical monotherapy for infections in cancer patients. Bucaneve G; Menichetti F; Minotti V; Pasticci MB; Tonato M; Del Favero A Chemotherapy; 1989; 35 Suppl 2():10-5. PubMed ID: 2612235 [TBL] [Abstract][Full Text] [Related]
51. Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin+aminoglycoside combination therapy for treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infections. Kreter B Clin Ther; 1992; 14(1):110-21. PubMed ID: 1576620 [TBL] [Abstract][Full Text] [Related]
52. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937 [TBL] [Abstract][Full Text] [Related]
53. Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group. Eur J Surg Suppl; 1994; (573):61-6. PubMed ID: 7524798 [TBL] [Abstract][Full Text] [Related]
54. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. Oliva ME; Rekha A; Yellin A; Pasternak J; Campos M; Rose GM; Babinchak T; Ellis-Grosse EJ; Loh E; BMC Infect Dis; 2005 Oct; 5():88. PubMed ID: 16236177 [TBL] [Abstract][Full Text] [Related]
55. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Liang R; Yung R; Chiu E; Chau PY; Chan TK; Lam WK; Todd D Antimicrob Agents Chemother; 1990 Jul; 34(7):1336-41. PubMed ID: 2201252 [TBL] [Abstract][Full Text] [Related]
56. [Imipenem-cilastatin in infections]. Armengaud M Presse Med; 1990 Apr; 19(13):629-33. PubMed ID: 2139945 [TBL] [Abstract][Full Text] [Related]
57. [Comparative study of the cost-effectiveness of initial therapy with imipenem/cilastatin in secondary peritonitis]. Rodloff AC; Kujath P; Lünstedt B; Gaus W Chirurg; 1998 Oct; 69(10):1093-100; discussion 1100. PubMed ID: 9833192 [TBL] [Abstract][Full Text] [Related]
58. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients. Kuo BI; Fung CP; Liu CY Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445 [TBL] [Abstract][Full Text] [Related]
59. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Balfour JA; Bryson HM; Brogden RN Drugs; 1996 Jan; 51(1):99-136. PubMed ID: 8741235 [TBL] [Abstract][Full Text] [Related]
60. [Imipenem/cilastatin sodium and other beta-lactams for respiratory tract infections: clinical benefit and treatment days for cure]. Oizumi K; Rikimaru T; Shiraishi T; Motohiro A; Yoshida M; Watanabe K; Maruyama R; Ishibashi T; Kitahara Y; Kido M; Yoshii C; Hara N; Ikeda A; Yamada H; Ninomiya K; Matsuzaki Y; Ichinose Y; Namba K; Kodama T; Kunitake R; Miyazaki N; Abe K; Matsunaga R; Ide H; Kamae I Jpn J Antibiot; 1999 Jan; 52(1):1-15. PubMed ID: 10202683 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]